Instil Bio (TIL) Other Non-Current Assets (2020 - 2026)
Instil Bio (TIL) posted quarterly Other Non-Current Assets of $4.0 million for Q1 2026, up 315.21% year-over-year from $960000.0 in Q1 2025, and up 2301.2% quarter-over-quarter from $166000.0 in Q4 2025.
Instil Bio (TIL) Other Non-Current Assets (2020 - 2026) Analysis & Trends
Instil Bio's Other Non-Current Assets history runs 7 years deep, the most recent figure standing at $4.0 million for Q1 2026.
- In Q1 2026, Other Non-Current Assets rose 315.21% year-over-year to $4.0 million; the TTM figure through Mar 2026 stood at $4.0 million (up 315.21% YoY), while the FY2025 annual figure was $166000.0, down 96.3% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $4.0 million, up from $166000.0 in the prior quarter.
- The five-year high for Other Non-Current Assets was $5.0 million in Q3 2022, with the low at $150000.0 in Q2 2025.
- The 5-year median for Other Non-Current Assets is $3.3 million (2022), against an average of $2.9 million.
- The sharpest annual moves came in 2025 and 2026: Other Non-Current Assets plunged 96.3% in 2025, then soared 315.21% in 2026.
- Instil Bio's Other Non-Current Assets stood at $3.4 million in 2022, then sank by 56.02% to $1.5 million in 2023, then jumped by 199.13% to $4.5 million in 2024, then slumped by 96.3% to $166000.0 in 2025, then soared by 2301.2% to $4.0 million in 2026.
- Business Quant data shows TIL's Other Non-Current Assets at $4.0 million in Q1 2026, $166000.0 in Q4 2025, and $4.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 65.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 104.44 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 62.96 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 202.31 Mn |
| 10 | Instil Bio | 50.29 Mn | 50.29 Mn | - | 3.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.91 Mn |
| Mar 31, 2026 | 3.99 Mn |
| Dec 31, 2025 | 166,000.00 |
| Sep 30, 2025 | 4.15 Mn |
| Jun 30, 2025 | 150,000.00 |
| Mar 31, 2025 | 960,000.00 |
| Dec 31, 2024 | 4.49 Mn |
| Dec 31, 2023 | 1.50 Mn |
| Sep 30, 2023 | 2.54 Mn |
| Jun 30, 2023 | 3.10 Mn |
| Mar 31, 2023 | 3.63 Mn |
| Dec 31, 2022 | 3.41 Mn |
| Sep 30, 2022 | 5.01 Mn |
| Jun 30, 2022 | 4.25 Mn |
| Mar 31, 2022 | 3.08 Mn |
| Dec 31, 2021 | 8.14 Mn |
| Sep 30, 2021 | 4.79 Mn |
| Jun 30, 2021 | 3.81 Mn |
| Mar 31, 2021 | 3.70 Mn |
| Dec 31, 2020 | 1.71 Mn |